A Statistical Evaluation of Dose Expansion Cohorts in Phase I Clinical Trials

作者：Boonstra Philip S^*; Shen Jincheng; Taylor Jeremy M G; Braun Thomas M; Griffith Kent A; Daignault Stephanie; Kalemkerian Gregory P; Lawrence Theodore S; Schipper Matthew J

来源：JNCI-Journal of the National Cancer Institute, 2015, 107(3): dju429.

DOI：10.1093/jnci/dju429

Background: Phase I trials often include a dose expansion cohort (DEC), in which additional patients are treated at the estimated maximum tolerated dose (MTD) after dose escalation, with the goal of ensuring that data are available from more than six patients at a single dose level. However, protocols do not always detail how, or even if, the additional toxicity data will be used to reanalyze the MTD or whether observed toxicity in the DEC will warrant changing the assigned dose. A DEC strategy has not been statistically justified.
Methods: We conducted a simulation study of two phase I designs: the "3+3" and the Continual Reassessment Method (CRM). We quantified how many patients are assigned the true MTD using a 10 to 20 patient DEC and how a sensible reanalysis using the DEC changes the probability of selecting the true MTD. We compared these results with those from an equivalently sized larger CRM that does not include a DEC.
Results: With either the 3+3 or CRM, reanalysis with the DEC increased the probability of identifying the true MTD. However, a large CRM without a DEC was more likely to identify the true MTD while still treating 10 or 15 patients at this dose level.
Conclusions: Where feasible, a CRM design with no explicit DEC is preferred to designs that fix a dose for all patients in a DEC.

• 出版日期2015-3